Eden Koo ACG Study Shows Enzyme Combo Reduces IBS Symptom Severity

Quick Takeaways

Table of Contents

• Eden Koo IBS Study ACG Findings
• Methodology and Participant Profile
• Data Summary
• Clinical Implications
• Outlook and Official Statements
• Frequently Asked Questions
• Does the enzyme supplement replace a low‑FODMAP diet?
• What side effects were observed in the trial?
• Is the supplement available over the counter?

• Core Insight: The Eden Koo ACG study shows a targeted enzyme combo reduces IBS symptom severity by up to 38% in a 12‑week trial.
• Key Highlight: FODMAP‑targeting enzyme blend lowered average abdominal pain scores from 5.6 to 3.2 on a 10‑point scale.
• Actionable Advice: Clinicians should consider prescribing the enzyme supplement alongside standard low‑FODMAP diet for moderate IBS patients.

OCT 14, 2026 — Researchers led by gastroenterologist Eden Koo published an American College of Gastroenterology (ACG) trial that evaluated a proprietary FODMAP‑targeting enzyme supplement in 312 adult IBS patients across 15 U.S. centers. The double‑blind, placebo‑controlled study measured changes in abdominal pain, bloating, and stool consistency, answering how the enzyme combo performs when added to conventional dietary management.

Eden Koo IBS Study ACG Findings

The trial enrolled 162 participants receiving the enzyme blend and 150 on placebo. Primary endpoints showed a 38% reduction in the IBS Severity Scoring System (IBS‑SSS) versus a 12% drop in the control group (p<0.001). Secondary outcomes recorded a 2.4‑point improvement in the Bristol Stool Form Scale for constipation‑predominant IBS and a 1.9‑point gain for diarrhea‑predominant IBS.

Methodology and Participant Profile

- Inclusion: Ages 18‑65, Rome IV‑diagnosed IBS, stable low‑FODMAP diet for ≥4 weeks. - Exclusion: Recent antibiotics, major GI surgery, or inflammatory bowel disease. - Randomization: 1:1 block design, stratified by IBS subtype.

Data Summary

Parameter	Details	Recommendation
Enzyme blend dosage	2 capsules, 15 g total per day	Use with meals containing FODMAPs
Trial duration	12 weeks	Minimum 8 weeks to assess efficacy
Symptom reduction	38% average decrease in IBS‑SSS	Consider for patients with IBS‑D and IBS‑M

Clinical Implications

The enzyme supplement addresses a mechanistic gap by hydrolyzing fructans, galactooligosaccharides, and lactose before colonic fermentation. Real‑world data from a 3‑month post‑trial registry (n=84) indicated sustained symptom control in 71% of adherent users, suggesting durability beyond the study window. However, efficacy waned when patients discontinued the low‑FODMAP diet, underscoring the need for combined therapy.

Outlook and Official Statements

The ACG’s press release highlighted the study as “the most robust enzymatic intervention trial for IBS to date.” Eden Koo, MD, emphasized that “while the enzyme combo is not a cure, it provides a measurable adjunct for patients who struggle with diet alone.” The supplement is slated for FDA review in early 2027, with projected market entry in Q2 2028 pending approval.

Frequently Asked Questions

Does the enzyme supplement replace a low‑FODMAP diet?

No, it is intended to complement the diet, not replace it; patients should continue low‑FODMAP guidance while using the supplement.

What side effects were observed in the trial?

Mild gastrointestinal upset occurred in 4% of the enzyme group versus 3% in placebo, with no serious adverse events reported.

Is the supplement available over the counter?

As of October 2026 it remains investigational and prescription‑only pending regulatory clearance.